CMC Regulatory Considerations for Antibody-Drug Conjugates Antibody-drug conjugates unite the specificity and long circulation time of an antibody with the toxicity of a chemical cytostatic or ...

The market is projected to grow from $11B in 2024 to $40B by 2030, driven by both conventional bispecifics and advancements such as antibody-drug and radioligand conjugates. 2 Invenra has launched ...

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd antibody-drug conjugate (ADC ... and controls (CMC) data pertaining to the drug product and manufacturing process.

Avidity Biosciences is a biopharma firm developing a new form of RNA therapy called antibody oligonucleotide conjugates (AOC ... that the US Food and Drug Administration (FDA) granted rare ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

Exclusive global license outside of Greater Chinafor MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) ...

Comparative outcomes of neuroendocrine tumors in the historically underserved population of Bronx, NY: Montefiore Einstein Comprehensive Cancer Center. Pamrevlumab ...

Antibody-RNA Conjugates represent a significant advancement in the treatment of challenging and rare diseases with unmet medical need.

Innovent has launched 13 products in the market. It has 4 new drug applications under regulatory review, 3 assets in Phase III or pivotal clinical trials and 17 more molecules in early clinical stage.